Skip to main content

Author: Marguerite Arnold

Luxembourg Wrestles With The Particulars Of Rec Legalization

The Grand Duchy of Luxembourg has a date with destiny – namely recreational reform by the fall of this year (legislatively at least). But the devil is, as always, in the details.

Here is the intriguing development. Theoretically, or at least legislatively, Luxembourg is supposed to approve a recreational cannabis market this fall. 

Where has this been heard before? Ah, yes, Canada, circa 2018. 

Indeed, according to insiders, the country has been looking abroad for examples of how to proceed. An article in a French pro cannabis zine reports this week that the Parliament continues to debate the topic. The pressure is certainly on. This one small country of 600,000 in the heart of the EU is due to have an outsize impact on the conversation – and everyone knows it.

While Covid has clearly delayed the debate (everywhere), in Luxembourg the stakes are high – starting for the political party (the Greens) who promised to make this all happen back in 2018 when they got elected. How time flies.

Indeed, Luxembourg is likely less to be like “Canada” and more like Colorado in the ongoing European model. Holland is currently playing the part of California, sans raids by the federales

No matter the analogy, and from where it is drawn, politicians of the “left” persuasion are now in the political hot seat to deliver. Reform in the Duchy must be passed.

A Tipping Point European State?

Luxembourg, no matter the particulars of its reform, and how to control and regulate the sales of cannabis, is clearly a tipping point moment in the entire debate for the European Union if not Europe – particularly with Switzerland lining up to follow suit just next year.

Once there is a test model, there will be something for (at least) the Germans to debate. However, reform in Luxembourg is not even what it was pre-pandemic. The hit to every European economy from the shutdowns is massive. Further, it is inevitable that there will be both societal as well as political shifting – including on the entire topic – almost exactly like there was in the Roaring Twenties of the last century.

Just because Luxembourg is doing it, however, is not going to be an excuse that is likely to fly smoothly at the Bundestag (for one). That said, Germany, Italy, and other countries where medical reform has now come will be in the front lines of the debate in a way that has not happened here, yet.

Be sure to book your tickets to the International Cannabis Business Conference when it returns to Berlin this August!

Spanish Government Moves To Formally Consider Medical Efficacy Of Cannabis

Last week, the Spanish Congressional Health and Consumer Affairs Commission Committee met to consider exploring the medical efficacy of cannabis. Will this finally move the needle on some type of formal, final Spanish reform?

It is odd looking at the developments in Spain with an American perspective but on the European side of the discussion. In some ways, the situation in the country is analogous to the period of reform that began to percolate about 2014. Namely, two American states had voted to change their state constitutions to make recreational cannabis legal. In the meantime, federal reform of even the medical kind remained elusive. To some extent this is the impact of the lobbying power of the recreational movement in the United States and the lack of a formal underlying federal healthcare system. However, it is also a testament to the general reluctance of federal level authorities to even acknowledge the same.

In Spain, a similar kind of situation is brewing. 

The club movement really began picking up steam along with the American recreational movement. The two main Spanish states in which clubs are found today are the two most independent. Basque country and the Catalan (Barcelona). 

The club movement has been hurt by Covid, but it is still operating, around the edges of “the law.” In the meantime, one of the organizers of the same must report to jail nightly after his human rights case was refused by the court in Strasbourg. However, moving events across the EU (see medical reform in Germany, and now France) as well as Albert Tió’s struggle domestically has ignited, finally, a desire on the federal level in Spain to address the overall issue.

Could Federal Reform Help Solve the Club Problem?

It appears that the powers that be in Spain might have gotten the memo that the entire situation as it stands, is more than a bit ridiculous. The Comision de Sanidad y Consumo has ample evidence, including at this point many European countries that have recognized the drug as having medical efficacy. At the EU level, CBD is no longer considered even a narcotic.

While it is unlikely that the Spanish government will move quickly, it is unlikely that Spanish authorities will not push the issue forward, finally, within the next 12 months. And by tipping a hand to modern science it is also likely that the entire club conversation will also then get added to the mix. Currently, there is no reliable data on what percentage of club clients are patients.

There is already a rec market in Holland. Within a year there will be two more (in Luxembourg and Switzerland).

While it is unlikely in other words that anything on a federal level will be transformative by the admission of medical efficacy by the Spanish government, it appears that the time has come, finally, for Spain to enter the 21st century on the basic issue of federal medical reform. It is unlikely that the clubs will be closed when that happens. And further, very possible that this will be the final trigger to push for regulation of the club system (like what has been seen in Holland).

Be sure to book your tickets to the International Cannabis Business Conference when it returns to Europe this summer.

It’s Critical That German CBD Law Matches EU Law

After a brew ha ha over hemp tea that made its way to federal court, there is a renewed call domestically to homogenize German law with European ruling. Is “Trickle Down Reform” from the EU a better way to handle cannabis reform?

In an indeterminate case in March, a case involving hemp tea made its way to the German federal court but the ruling did not clear up the status of hemp in the country. It is still considered a “narcotic” under German law (even though on a European level this has now been cleared up).

The case however is indicative of a larger problem that exists across Europe. The first is that the status of cannabis generally has not been determined across the region. The ruling on CBD by the European Commission last fall may have given the EU its “2018 Farm Bill” but there are much bigger issues to deal with still in the room. Think, for example, how largely ineffective the U.S. legislation has been with dealing with the vast majority of problems facing just the American industry.

This is why the European Cannabis Association was formed (to begin to move the bigger ticket items forward from cultivation through end distribution). There is an urgent need to do the same as even the Spanish government is finally moving (as the last larger economy in Europe) to recognize the medical efficacy of the plant.

Beyond that, however, there is then the problem of adoption of sovereign states of any European-wide decision on cannabis. In this case, the cry has been taken up by the hemp company involved in the German case as well as the German Cannabis Industry Association.

It is clear that it is critical that German law be in alignment with EU-wide decrees on cannabis – but what is the best approach to make this happen? Is hemp the real door opener, or rather cannabis generally? And further, now that EU policy has been set on the same, why focus on anything other than comprehensive reform and policies?

If the US is any indication, it is discussions about the entire plant which make a real difference. Without regulation on a federal level, the U.S. states are proceeding on policies that themselves will have to be changed again with a national policy change. The “hemp exception” made zero difference in any state in the U.S. when it has come to actual reform. Indeed, this has been used as window dressing to stave off the larger discussions – namely all of the ones involved in comprehensive regulation except for the level of THC allowed in hemp.

This means that in Europe, it is critical for sovereign organizations and groups to begin to unite under a single umbrella to push reform at a regional level, and in Brussels. And for the whole plant, not just part of it.

Indeed, in the recent tea case, it was the EU decision that was the deciding case law, not the German Narcotics Act. While it is painful for individual members of the industry to get caught in changing gears of regulatory requirements, it is also critical for the companies within it to realize that organization in Europe must happen regionally first, not locally, for real change to come at a legislative and legal level now.

Be sure to book your tickets now to the International Cannabis Business Conference when it returns to Europe this summer.

Cannabis Tea With The Queen?

GW Pharmaceuticals wins the prestigious Queen’s Award for Enterprise 2021 – what next for the British market?

GW Pharmaceuticals, the sole British medical cannabis cultivator and producer, known mostly for Sativex and Epidiolex – has been granted a prestigious award. Namely the Queen’s Award for Enterprise. For those unfamiliar with the prize, it is a tradition that has been around since 1966 when it was first established, by Royal Warrant, to promote British companies who exported their products.

The fact that a cannabis company might win the award is, in its own way, an industry first. However, when it comes to the history of GW Pharma, this should not be surprising. The company was established at the end of the last century as the only British company that could cultivate cannabis for pharmaceutical purposes.

Today, the company’s drugs for MS (Sativex) and a form of child epilepsy (Epidiolex) are exported globally. 

The biggest problem of course for acceptance – if not sales? Both drugs are on the highly expensive side of the equation. So much so that the country’s own health department – the National Health Service – did not cover it until a bulk purchase with the company could be negotiated (within the last 24 months).

Studies have also shown that drug tolerance (within a year) is an issue the company has still to negotiate.

Beyond that of course, the politics around creating a monopoly on medical cannabis production while denying the same medicine to the British public (also while former Prime Minister Theresa May’s husband was a major shareholder) has always rankled the rest of the industry. 

The reality? Reform so far in the UK has come, in fact, in spite of, not because of GW Pharma.

What Next?

At this point, after several years of imports from other places – starting with cannabis oil that treats epilepsy and other conditions that GW Pharma medications do not – the entire cannabis discussion is already more than just one company.

Both cultivation and extraction facilities are getting off the ground – and obtaining hard to get certifications that will allow them to compete with GW Pharma for the first time. 

Beyond that, cannabis reform at least of the decrim kind is at least on the agenda of the newly elected Mayor of London Sadiq Khan. 

GW Pharma, in other words, may have won the right to have tea (or at least an audience) with good Queen Lizzie. In the meantime, the rest of the industry is evolving around it.

Be sure to book your tickets now for the International Cannabis Business Conference when it returns to Europe – Summer 2021!

Covid And Cannabis Travel This Summer

The European Commission intends to let fully vaccinated US travelers visit the European Union this summer – book your tickets now for the International Cannabis Business Conference!

In an unbelievably good sign for the overall cannabis industry as well as our conference, we are getting further confirmation that the travel corridors will be opening across Europe this summer – including for foreign visitors and for whatever purpose.

According to the reliable website Schengen Visa Info, Ursula von der Leven has announced that all vaccinated third-country citizens will be able to enter the EU for non-essential purposes.

On May 3, the European Commission presented a proposal to its Member states to allow the gradual reopening of borders for citizens of any country who have been vaccinated by one of the medicines approved by the European Medicines Agency.

This means that vaccinated travelers from non-EU countries like the US and the UK can travel to the EU by the end of June.

How to Check Avails for The International Cannabis Business Conferences?

This announcement is undoubtedly good news – and for those still waiting for some kind of signal before signing up for the conference – a final confirmation that the International Cannabis Business Conference will again rock the house across Europe this year.

However, entry to Europe is not the only consideration. So is re-entry to your home country. Check local rules and guidelines. However, this announcement by European Authorities is a good sign that other countries will continue to reform their travel corridor guidelines as the number of infections stays relatively steady and Europe begins to roll out its own vaccine programs.

A Sense of “Getting Back to Normal”?

The reality is that the evolving European cannabis industry is no stranger to the kinds of regulations and hurdles now placed in front of just about everyone because of the Pandemic. Which cannabis can cross which borders and under what circumstances have become the watchword of the German cannabis industry for starters.

Beyond that, of course, the industry has hit various snags and delays because of the Pandemic, including licensing approvals as well as the all-important networking that has so far evolved the industry to where it is today.

While it is inevitable that the Pandemic has not run its course – and there will be future travel restrictions and other complications – this announcement by the EU means that at least this summer, the cannabis industry itself can meet, network, and forward the agenda and next steps of what is yet to come.

The industry never sleeps.

Be sure to book your tickets for the International Cannabis Business Conference in Europe this summer!

First Cannabis Patient Makes Bid For Home Grow In Spain

A 49-year-old male patient has made his application for medical home grow to the Spanish Medicines Agency public

Juan Manuel Rodriguez, a Gen X Spanish citizen, has just made his application for a cannabis home grow license to the Spanish Medicines Agency public. Rodriquez has been confined to a wheelchair for thirty years after a tragic accident when he was 19.

He is making his legal claim under the 1967 Spanish law (in other words a pre-constitutional law) which allows for the use of medical cannabis if specifically authorized by the federal drugs and medical devices agency.

The plea could not come at a more contentious time.

The Situation in Spain

Much like the Dutch market, the Spanish cannabis club environment has developed within the grey areas of national law. The most recent high-profile case in court, filed by activist Albert Tió, at the European level, went down in flames last month. In the meantime, the club scene is caught in disarray because of the Pandemic domestically. And beyond Spanish borders the issue of regulation is also moving in several European countries (see Holland, as of next year, both Luxembourg and Switzerland).

The activists on the ground know there is an opening – and are continuing to support legal challenges and applications of all sorts – including Rodriguez’ – and presumably those who will follow suit.

The application may finally be the tipping case to move the entire conversation forward – but it also may not. While severely disabled patients usually have a good case to make – and have often moved the needle (see Germany as a prime example of the same on a European level) – it is most often not adults but children who manage to put enough political pressure on governments to change the law. See the UK, but also see Israel where, in 2014, enough parents threatened to immigrate to the American state of Colorado that the Israeli government changed its policies within weeks.

That is not likely to be the case in Spain. However, what is clear is that the status quo is increasingly being challenged by individuals who obviously have a medical and economic need. 

Even in Spain in other words, prohibition is dying a death of a thousand cuts – one challenge at a time.

Be sure to book your tickets to the International Cannabis Business Conference events in Europe in 2021!

The Belgian Cannabis Discussion: A Step Towards Modernizing A National Drug Policy

The country between Holland and Luxembourg is now caught up in its own re-examination of its cannabis policy.

Belgium may be finally moving to formalize its cannabis policy. The country of 11.5 million people is far from the front lines of even the European cannabis debate – but that might now be changing as the Senate approves an evaluation of a 100-year-old drug law.

In late February, a law case made headlines in the European cannapress. On February 24th, on a ruling on appeal, the eleven ex-members of the oldest cannabis social club in the country – Trekt Uw Plant – were found guilty of cannabis cultivation and sale but were released without further charges. The decision is being hailed as the final legal nail in the coffin for the country’s existing drug law.

The club itself has a long history. It was founded in 2006, as the first Belgian social club, three years after the first real reform in the country (individuals could possess one female plant for personal consumption). The club was subsequently prosecuted twice – in 2008 and 2010 – but exonerated both times. Indeed, the Public Prosecutors office declared in 2012 that it was bound to accept the activities of the club. However, in 2017, three members were arrested leading to the prosecution of twenty individuals and jail terms of 20 months each. This final legal action, no matter the final release and essential pardon of those convicted, financially ruined the organization.

Where to Go from Here?

Cannabis is one of the most popular controlled substances in the country. Technically the plant is still illegal, however, adults over the age of 18 can possess 3 grams. In 2015, a royal decree allowed for the medical use of cannabis but was limited to Sativex only (a pharmaceutical produced by the British company GW Pharma).

Further, it is very clear that the Belgian model is now in the same area, both legally and commercially of both the Spanish and Dutch model – namely still in a grey part of the law. Further, it is also increasingly clear that this situation cannot continue forever, particularly given moving case law and sovereign decisions of neighbouring European countries.

In the next 12-24 months, in other words, look for a new policy shift on the Belgian front – and further in a direction that may create another canna-friendly regime – or at least more of one, in yet another member state of the EU.

Be sure to book your tickets for the upcoming International Cannabis Business Conference events in Europe this summer!

Holland Moves Forward With Legitimizing Its Federal Cannabis Market

Several developments are underway that indicate that despite multiple ball drops, the Dutch government is committing to regulating the recreational cannabis industry – and that has huge European-wide implications.

For those who have been wondering, there is beginning to be a little clarity if not light on the evolving situation in Holland on the matter of a federal regulatory infrastructure if not policy to regulate the coffee shops.

Here is the first development. The tender bid in Holland has been almost as much of a disaster if not lawsuit strewn as the German version (to regulate medical). That said, there seems to be forward progress here too. After Aurora got fined for filing a frivolous lawsuit, it appears that the top contenders have been selected (after one dropped out).

This is not the end of the story, however. The situation is still as hazy as day-old bong smoke – namely, while the federal government will have oversight of the ten vendors selected and their supply chains, this still leaves out any and all of the industry operating in the largest cities.

That dichotomy too, however, is on the cards to change as well. Indeed, on June 2, members of the Dutch Parliament are meeting to discuss how the federal government will set cannabis policy for the country. Presumably, in other words, finally a federal move to consolidate the entire national industry.

This is a major, major development, no matter who has thrown shade at the process so far.

It is a frank admission, finally, among other things, that federal governments must get in front of, rather than lag behind on all things cannabis policy related. And at this point, even in Europe, that also includes the recreational discussion.

Why A Medical Reference Point Is So Important Going Forward

All of these things being said, the reality is that the development of the formal, medical market in Europe means that there is some basis in science for what then is used in any recreational market (from Holland and Luxembourg to Switzerland and beyond).

And in Europe, generally, that discussion has only just gotten started.

For example, in Switzerland, as the country begins to gear up for its recreational trial next year, the reference data on allowances for users has clearly come from the Canadian medical market (not the German one). The German one, by contrast, is currently half of the recommendations of the Canadian government (not to mention Israeli patient data).

This means, in other words, that an evolving if blended rec-medical market is going to move the needle here in the EU in a very different way – and have a lasting impact first on not the recreational but indeed, the medical market.

Be sure to book your tickets now for our International Cannabis Business Conference events! The International Cannabis Business Conference returns to Berlin in July 2021!

Ukraine Delays Medical Cannabis Legalization Vote

Government again pushes can down the road as top officials deliberately delay serious discussion on basic medical cannabis reform.

Cannabis reform in Ukraine is continuing to be painfully slow. The cabinet has again delayed a meaningful vote on reform after promising the same in April – and which, ultimately, is a bunch of legislative text with really no meaning. Certainly not for patients, much less the nascent industry that lies behind this.

There are several debates afoot in Ukraine right now and at high levels over cannabis – namely, whether synthetic drugs are better options – and whether to craft a market based solely on the same. At a deeper level, this discussion is about the right to grow cannabis at all – much use it in a form that is not pharmacized in some fashion – even for medical use.

The fight on the ground right now is one of the most contentious left in the world as a result. And this is over basic medical CBD access for child epileptics. When it comes to any form of THC, officials are referring to older, cannabinoid-containing drugs that are not only expensive but not as effective for a wide range of conditions as say, whole plant medication.

For all the advances, in other words, in certain parts of Europe if not the rest of the world, it is often easy to find reflections of a past world that no longer exists.

Given the spreading understanding of cannabis as medicine, who really, would convict a desperate parent for growing hemp in the basement to help their desperately sick child?

How Can Broader Cannabis Reform Be Promoted Globally?

The situation in Ukraine has been bubbling for some time – with German activists (in particular) if not members of the industry actively seeking some way to help those on the ground. 

Here is the good news. The world has changed, rather dramatically, in the last 14 months, and it is not going to just go back. Digital networks, education, and a sense of building a new kind of medicine if not medicine delivery is all now on the front burners of governments everywhere. Cannabis and cannabis reform features prominently in all these discussions.

In the meantime, those on the ground fight on, facing a familiar feeling if not battle. This time, however, the world is watching.

Be sure to book your tickets now to upcoming International Cannabis Business Conference events!